Phillip Tai

Dr. Phillip Tai is an Assistant Professor at UMass Chan Medical School, with appointments in the T.H. Chan School of Medicine's Department of Genetic and Cellular Medicine and Department of Microbiology, as well as the Morningside Graduate School of Biomedical Sciences' Interdisciplinary Graduate Program. His laboratory focuses on virology and vectorology of adeno-associated viruses, with research that bridges basic science and therapeutic applications.

Dr. Tai received his BA in Molecular Cellular Biology from the University of California, Berkeley, and his PhD in Biochemistry from the University of Washington. His educational background provided the foundation for his current research in gene therapy vectors and viral delivery systems.

His research interests center on adeno-associated virus (AAV) vector development, with particular emphasis on capsid engineering, vector production optimization, and tissue-specific targeting. His work spans fundamental virology, molecular biology, and translational applications for treating genetic disorders. Current projects include developing novel AAV capsids with improved tissue targeting capabilities, optimizing vector production systems for clinical applications, and investigating safety profiles of viral vectors for gene therapy.

Analysis of Dr. Tai's recent publications reveals a strong focus on AAV vector engineering and production methodologies. His research demonstrates consistent advancement in understanding viral vector heterogeneity, capsid modifications for improved delivery, and tissue-specific targeting strategies. The publications show increasing sophistication in analytical techniques, with growing use of next-generation sequencing methods to characterize viral vectors at the molecular level.

Dr. Tai actively collaborates with prominent researchers in the field, including Guangping Gao (his primary collaborator), Jun Xie, and Dan Wang. His work has significant implications for gene therapy applications across multiple disease areas including liver diseases, neurological disorders, and ocular conditions.

His laboratory maintains an active research program with multiple ongoing projects related to AAV vector development. The lab focuses on both fundamental virology questions and translational applications, with particular attention to vector safety, production efficiency, and tissue-specific delivery mechanisms.